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Abstract
Background: UK NHS Stop Smoking Services provide cost effective smoking cessation interventions but, as yet, there 
has been no assessment of their provision of relapse prevention interventions.
Methods: Electronic questionnaire survey of 185 UK Stop Smoking Services Managers.
Results: Ninety six Stop Smoking Service managers returned completed questionnaires (52% response rate). Of these, 
58.3% (n = 56) ran NHS Stop Smoking Services which provided relapse prevention interventions for clients with the 
most commonly provided interventions being behavioural support: telephone (77%), group (73%), and individual 
(54%). Just under half (48%, n = 27) offered nicotine replacement therapy (NRT), 21.4% (n = 12) bupropion; 19.6% (n = 
11) varenicline. Over 80% of those providing relapse prevention interventions do so for over six months. Nearly two 
thirds of all respondents thought it was likely that they would either continue to provide or commence provision of 
relapse prevention interventions in their services. Of the remaining respondents, 66.7% (n = 22) believed that the 
government focus on four-week quit rates, and 42.9% (14 services) believed that inadequate funding for provision of 
relapse prevention interventions, were major barriers to introducing these interventions into routine care.
Conclusions: Just over half of UK managers of NHS Stop Smoking Services who responded to the questionnaire 
reported that, in their services, relapse prevention interventions were currently provided for clients, despite, at that 
time, there being a weak evidence base for their effectiveness. The most commonly provided relapse prevention 
interventions were those for which there was least evidence. If these interventions are found to be effective, barriers 
would need to be removed before they would become part of routine care.
Background
The effectiveness and cost-effectiveness of UK NHS Stop
Smoking Services in providing support for smokers wish-
ing to stop have been demonstrated, with more than half
of English services' clients achieving self-reported absti-
nence from smoking for at least four weeks[1,2] However,
quitters' rates of relapse to smoking are high, with around
75% of those abstinent at four weeks after their quit date
re-starting smoking by one year[1]. The use of effective
treatments to reduce rates of relapse to smoking (which
we refer to here as relapse prevention interventions,
could greatly improve long term cessation rates for the
NHS Stop Smoking Services.
A Cochrane review found no clear evidence for behav-
ioural relapse prevention interventions being effective
and only relatively weak evidence that some medications,
effective for smoking cessation, may also be effective as
relapse prevention interventions when provided for
extended periods to smokers who had achieved short-
term abstinence[3]. W e recently completed a review of
the evidence base for relapse prevention interventions
using a similar search strategy to the Cochrane review,
but restricting included studies to those involving absti-
nent smokers only, and synthesising data from similar fol-
low up time points only, rather than aggregating final
follow up data collected at different times as the
Cochrane review did[4]. We found that, amongst individ-
uals who had stopped smoking without any cessation
support, behavioural self help relapse prevention inter-
ventions were effective and varenicline, bupropion and
nicotine replacement pharmacotherapy interventions
also were effective for preventing relapse to smoking
amongst smokers who had achieved abstinence using
drug treatments.
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As little was known about either the current provision
of relapse prevention interventions in UK NHS Stop
Smoking Services or the feasibility of adding these to
existing treatment options, we carried out a small qualita-
tive study with a convenience sample of 16 Stop Smoking
Service managers[5] to explore these factors. We found
that managers had no shared understanding of either the
concept of relapse prevention or the kinds of interven-
tions that should be used to prevent relapse, but there
was interest in relapse prevention interventions and a
willingness to make these available to stop smoking ser-
vices' clients and this was already happening in some
areas. Consequently, in this study, we aimed to quantify
the current provision of relapse prevention interventions
within the Stop Smoking Services in the UK and ascertain
the feasibility of introducing them to services where they
were not currently provided. To overcome the lack of a
shared understanding of relapse amongst NHS Stop
Smoking Service staff, we defined relapse prevention
interventions as behavioural or drug therapies delivered
after acute smoking cessation treatment has ended and
resulted in abstinence from smoking.
Methods
For the benefit of international readers, Additional file 1:
Box 1, gives brief details regarding the characteristics of
UK NHS Stop Smoking Services [6] and all service man-
agers were asked to complete an electronic questionnaire.
From the emergent findings of our systematic review[4]
and qualitative research referred to above[4,5] issues of
potential importance to the provision of relapse preven-
tion interventions were identified and, from these, a
structured questionnaire (Additional File 2), was devel-
oped (which was available online at http://www.smok-
ingcessationmanagers.org). The questionnaire was
designed to obtain information pertaining to current pro-
vision of treatment for smoking cessation as well as cur-
rent and future relapse prevention treatment provision.
The questionnaire also asked about the feasibility of pro-
viding the most promising relapse prevention interven-
tions (identified from the reviews and qualitative research
as NRT, bupropion, varenicline, group and individual
behavioural counselling, and NRT combinations) in rou-
tine clinical practice. A clear definition of relapse preven-
tion was given, namely "Relapse Prevention
Interventions (or Relapse Prevention Treatments) are
behavioural or drug therapies delivered after acute
smoking cessation treatment has ended and resulted in
abstinence from smoking. Relapse Prevention Inter-
ventions therefore seek to reduce relapse to smoking
among abstinent smokers". We also distinguished
relapse prevention interventions from interventions
delivered to smokers who had briefly lapsed to smoking
(i.e. were not abstinent) and which aimed to prevent a full
relapse to smoking; respondents were asked to indicate
provision of any such lapse-orientated interventions/
treatments. An email with a flyer advertising the survey
and a link to the survey homepage was sent out to a total
of 185 managers in December 2008. Non-respondents
were followed up via a reminder email and telephone call
inviting them to visit the survey homepage and complete
the survey. Responses were anonymous and data were
summarised descriptively using SPSS version 16.0 for
Windows[7]. No hypotheses testing statistical analyses
were performed, but some comparisons are presented for
descriptive purposes.
Results
A total of 96 managers completed the survey (52%
response rate). Fifty four managers responded to the first
survey email and completed the online questionnaire. A
further 42 respondents completed the survey following
the reminder email and telephone call.
Current provision of smoking cessation and relapse 
prevention treatments
The vast majority of services provided both behavioural
and pharmacotherapy interventions for initial cessation
treatment. More than half of respondents, 58.3% (n = 56)
reported that their services currently provided relapse
prevention interventions with behavioural interventions
being preferred over the pharmacotherapies (Table 1). Of
those providing relapse prevention interventions, 60.7%
(n = 34) stated that these were offered to abstinent smok-
ers for as long as these clients perceived they required
them, 25.0% (n = 14) for 3-6 months and one service
(1.8%) did so for three months or less. Of the 40 services
reporting that they did not currently provide relapse pre-
vention interventions, 42.5% (n = 17) had provided such
interventions in the past and cited the following reasons
for no longer offering this kind of support: pressure to
meet government targets, poor client attendance, inade-
quate funding, and a belief that relapse prevention inter-
ventions are ineffective (Table 2).
Managers that responded to the first survey email were
compared to those that completed the survey after a
reminder telephone call. There was no association
between timing of responses and relapse prevention pro-
vision (Odds ratios (OR) 0.77; 95% confidence interval
(CI) 0.34 to 1.75).
Current provision of treatment for brief lapses
A large percentage of UK NHS Stop Smoking Services,
77.1% (n = 74) also provided treatment for clients who
had suffered a brief lapse to smoking. Of these, 72.9% of
services (n = 70) indicated the types of support provided:
one to one sessions (32.8%, n = 23); rolling groups and
drop-in sessions (7.1%, n = 5); telephone support (8.5%; nAgboola et al. BMC Health Services Research 2010, 10:214
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= 6); combinations of pharmacotherapy, telephone sup-
port, and one to one behavioural counselling (15.7%, n =
11); while 35.7% (n = 25) services continued acute cessa-
tion treatment. Although managers who provided relapse
prevention interventions were also more likely to report
providing treatment for brief lapses than those not pro-
viding relapse prevention interventions, this was not sta-
tistically significant (OR) 1.55; 95% CI 0. 59 to 4.04, P =
0.37).
Managers who responded to the first survey email did
not differ from those that responded to the telephone
reminder in terms of treatment of brief lapses (OR 1.92;
95% CI 0.70 to 5.26).
Feasibility of providing relapse prevention interventions
Respondents were asked to indicate the likelihood of
future relapse prevention intervention provision within
their service. Managers who had indicated that relapse
prevention interventions were not currently provided
were asked to indicate the likelihood of providing these in
the future and those already providing relapse prevention
interventions were asked about the likelihood of continu-
ing this. Nearly two - thirds, 65.6% (n = 63) of managers
thought it very likely or likely that they would continue to
provide, or start to provide relapse prevention interven-
tions in their services, while 34.4% (n = 33) of services
were not sure or thought it unlikely that they would pro-
vide these interventions in the future. There was no asso-
ciation between managers who responded to the first
survey email and those who responded to the second sur-
vey email in terms of likelihood of future relapse preven-
tion provision (OR 1.05; 95% CI 0.45 to 2.46).
Managers who wished to discontinue or not to begin
relapse prevention support cited the following reasons:
cessation orientated targets focussed on four week quit
rates (66.7%, n = 22); inadequate funding (42.9%, n = 14);
and the fact that clients had usually relapsed before they
re-contacted the cessation service (24%, n = 8).
These 33 respondents who indicated that they were not
sure or thought it unlikely that their services would pro-
vide relapse prevention interventions in the future, were
then asked to assume that barriers to provision of these
interventions were removed, and to hypothesise, in this
instance, which of these interventions they might encour-
age their NHS Stop Smoking Service to offer to abstinent
quitters after smoking cessation treatment. Table 3
reports their responses.
Discussion
Summary of findings
About half of the services surveyed reported providing
relapse prevention interventions despite, at the time of
the survey, their being only a weak evidence base for their
effectiveness and no guidance as to whether or not this
kind of support should be provided within the UK Stop
Smoking Services. The relapse prevention interventions
provided most frequently were telephone and individual
behavioural counselling although, at the time of the sur-
vey there was no evidence for the effectiveness of these
interventions (i.e. from the Cochrane review) and this has
not changed with our subsequent review. Many managers
were positive about either offering relapse prevention
interventions within the NHS or potentially introducing
these in the future and the most commonly cited reasons
for not providing or wanting to provide these interven-
tions were that: NHS Stop Smoking Services' targets are
focussed on achieving short periods of cessation by
Table 1: Provision of acute cessation treatment and relapse prevention treatment in UK NHS Stop Smoking Services
Type of Treatment
% (n)
Individual behavioural 
counselling
Group behavioural 
counselling
Telephone 
counselling
Nicotine Replacement 
Therapy
Bupropion Varenicline
Acute 
Cessation
99% (95) 87.5% (84) 81.2% (78) 97.9% (94) 86.5% (83) 92.7% (89)
Relapse 
Prevention
73.2%(41) 53.6% (30) 76.8% (43) 48.2% (27) 21.4% (12) 19.6% (11)
Table 2: Reasons for discontinuation of relapse prevention 
treatment
Reason % (n)
Pressure to meet targets 64.7% (11)
Poor client attendance 70.6% (12)
Inadequate funding 29.4% (5)
Ineffectiveness of relapse 
prevention interventions
17.6% (3)Agboola et al. BMC Health Services Research 2010, 10:214
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smokers and inadequate funding for relapse prevention
support, rather than the relatively weak current[3,8] evi-
dence base for the effectiveness of relapse prevention
interventions.
Strengths and Limitations
Approximately 50% of survey recipients did not respond
and, consequently, the reported rates of interest in and
provision of relapse prevention interventions may be
overestimated as managers with little interest in provid-
ing relapse prevention interventions might have been less
likely to respond. A greater response rate may have pro-
duced more varied results; non-responders to the survey
may have different experiences of providing relapse pre-
vention interventions in their services, although a com-
parison of the two waves of responses to the survey
showed that there were no differences in variables rele-
vant to the survey. Also amongst respondents, some
managers may have been unwilling to reveal that they do
not provide some form of relapse prevention intervention
in their services. However, we believe that biases in the
reporting amongst respondents are unlikely as, at the
time of the survey, using such interventions was not stan-
dard stop smoking service practice and no official guid-
ance recommended their use. The questionnaire used
mainly closed ended questions as these are less time con-
suming to complete and help to optimise completion
rates[9] but provided an "other" option for respondents to
provide additional information where none of the avail-
able options fit the manager's response. Closed ended
questions may restrict the respondents to the choices
provided, but we do not believe this is the case, because
we provided respondents with an "other" option with
space for free text which gave managers the opportunity
to expand on their response, and greater freedom of
expression[10].
Despite these limitations, we believe that the survey is
important; it is the first study to investigate the provision
of relapse prevention interventions in UK NHS Stop
Smoking Services and now that there is evidence that
some of these interventions may be effective[4], findings
can be used to facilitate the introduction of evidence
based ones into the services.
There is no previous research on this topic from the UK
and, we believe, internationally as the World Health
Organization report on the global tobacco epidemic pro-
vides no information on the provision of relapse preven-
tion interventions [11]. We could identify no similar
studies internationally which described the provision of
relapse prevention interventions in routine clinical prac-
tice, so it is difficult to make comparisons. The reasons
why such a high proportion of managers reported offer-
ing relapse prevention interventions which had no proven
evidence base are unknown and may be worth further
exploration. For example, this could reflect a desire to do
'something' to remedy high relapse rates from acute ces-
sation treatment, or their anecdotal experience of the
effectiveness of relapse prevention interventions, or a
perception that smokers appreciate being offered such
treatment. As managers favoured behavioural over drug
treatments, this suggests that, with smoking cessation
services configured as they are currently, it may be diffi-
cult to encourage the use of pharmacological interven-
tions for relapse without there being clear guidance on
this. Almost 77% of respondents working in services that
delivered relapse prevention interventions provided tele-
phone counselling which could be explained by the find-
ing that most services provided telephone support to aid
cessation and this may have been relatively easy and inex-
pensive to extend. Clearly, integrating effective pharma-
cological interventions into routine clinical practice has
cost implications and might be more challenging.
Table 3: Likelihood of providing relapse prevention interventions in the absence of barriers
Intervention Very Likely/Likely
% (n)
Not sure/Unlikely/Definitely not
% (n)
Individual Counselling 78.8% (26) 18.2% (6)
Group counselling 72.7% (24) 27.2% (9)
NRT 57.6% (19) 33.3% (11)
Bupropion 21.2% (7) 72.7% (24)
Varenicline 24.2% (8) 75.8% (25)
NRT combinations 54.5% (18) 39.4% (13)Agboola et al. BMC Health Services Research 2010, 10:214
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Conclusions
Current provision of acute cessation treatment largely
reflected UK guidance (NICE, SCOTTISH NICE[12], DH
Monitoring guidance[13]) and our survey suggests that
similar evidence based guidance is needed to support
managers wishing to provide relapse prevention interven-
tions in order to ensure that, in the future, the most
promising and effective interventions can be introduced
into routine care. Further research is required to solidify
current evidence on the effectiveness of relapse preven-
tion interventions and then to explore further the feasi-
bility and cost - effectiveness of introducing these in the
NHS Stop Smoking Services. Should relapse prevention
interventions be found to be cost - effective and accept-
able for use by abstinent smokers in the NHS Stop Smok-
ing Services the perceived barriers would need to be
removed.
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